Holocene Advisors LP Acquires Shares of 219,245 Qiagen (NYSE:QGEN)

Holocene Advisors LP acquired a new stake in shares of Qiagen (NYSE:QGEN) during the third quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund acquired 219,245 shares of the company’s stock, valued at approximately $9,991,000. Holocene Advisors LP owned approximately 0.10% of Qiagen at the end of the most recent quarter.

A number of other institutional investors also recently added to or reduced their stakes in QGEN. Victory Capital Management Inc. boosted its holdings in Qiagen by 104,759.6% during the second quarter. Victory Capital Management Inc. now owns 1,583,380 shares of the company’s stock valued at $65,061,000 after purchasing an additional 1,581,870 shares in the last quarter. Nuance Investments LLC grew its position in Qiagen by 17.3% during the 2nd quarter. Nuance Investments LLC now owns 5,271,494 shares of the company’s stock worth $216,606,000 after acquiring an additional 778,005 shares during the last quarter. Point72 Asset Management L.P. grew its position in Qiagen by 148.8% during the 2nd quarter. Point72 Asset Management L.P. now owns 1,184,806 shares of the company’s stock worth $48,684,000 after acquiring an additional 708,533 shares during the last quarter. Earnest Partners LLC grew its position in Qiagen by 11.1% during the 2nd quarter. Earnest Partners LLC now owns 3,807,284 shares of the company’s stock worth $156,441,000 after acquiring an additional 379,679 shares during the last quarter. Finally, DekaBank Deutsche Girozentrale grew its position in Qiagen by 12.2% during the 2nd quarter. DekaBank Deutsche Girozentrale now owns 3,248,354 shares of the company’s stock worth $133,292,000 after acquiring an additional 353,280 shares during the last quarter. 70.00% of the stock is owned by institutional investors and hedge funds.

Analyst Ratings Changes

A number of equities research analysts recently commented on QGEN shares. HSBC lowered Qiagen from a “buy” rating to a “hold” rating and set a $49.00 price target on the stock. in a research report on Thursday, October 17th. Hsbc Global Res upgraded Qiagen to a “hold” rating in a research report on Thursday, October 17th. Four equities research analysts have rated the stock with a hold rating and six have given a buy rating to the company’s stock. According to MarketBeat, the company has a consensus rating of “Moderate Buy” and an average price target of $50.88.

Qiagen Stock Performance

QGEN stock opened at $43.29 on Wednesday. The business’s fifty day moving average is $43.17 and its 200-day moving average is $43.66. The company has a quick ratio of 1.89, a current ratio of 2.17 and a debt-to-equity ratio of 0.39. The company has a market cap of $9.88 billion, a P/E ratio of 111.00, a price-to-earnings-growth ratio of 3.38 and a beta of 0.35. Qiagen has a twelve month low of $39.03 and a twelve month high of $47.44.

Qiagen Profile

QIAGEN N.V. offers sample to insight solutions that transform biological materials into molecular insights worldwide. The company provides primary sample technology consumables, such as nucleic stabilization and purification kits for primary sample materials, manual and automated processing for genotyping, gene expression, and viral and bacterial analysis, as well as silica membranes and magnetic bead technologies; secondary sample technology consumables, including kits and components for purification of nucleic acids from secondary sample materials; and instruments for nucleic acid purification and accessories.